Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2900644 | 0.87 | MMP1 (0.41) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL18378814 | 0.82 | MMP1 (0.46) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL2529030 | 0.81 | MMP1 (0.39) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL2529024 | 0.81 | MMP1 (0.39) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL1866046 | 0.81 | ALDH1A1 (0.52) | NAAATDP1ALDH1A1MAPTMAPK1 | |
| SCHEMBL18338892 | 0.81 | MMP1 (0.39) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL95383 | 0.81 | ALDH1A1 (0.52) | NAAATDP1ALDH1A1MAPTMAPK1 | |
| SCHEMBL2531293 | 0.79 | NAAA (0.41) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL17891962 | 0.79 | RARB (0.42) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL28864168 | 0.79 | CYP1A2 (0.41) | MMP1MMP2MMP3MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591426-B2 | Copolymer, wetting agent, medical device, and method for producing same | TORAY INDUSTRIES, INC. (JP) | 2023-02-28 | — | — | US | disclosed |
| EP-3438144-B1 | COPOLYMER, WETTING AGENT, MEDICAL DEVICE, AND METHOD FOR PRODUCING SAME | TORAY INDUSTRIES (JP) | 2021-06-30 | — | — | EP | disclosed |
| US-20210015960-A1 | COPOLYMER, WETTING AGENT, MEDICAL DEVICE, AND METHOD FOR PRODUCING SAME | TORAY INDUSTRIES, INC. (JP) | 2021-01-21 | — | — | US | disclosed |
| US-20190099511-A1 | COPOLYMER, WETTING AGENT, MEDICAL DEVICE, AND METHOD FOR PRODUCING SAME | TORAY INDUSTRIES, INC. (JP) | 2019-04-04 | — | — | US | disclosed |
| EP-3438144-A1 | COPOLYMER, WETTING AGENT, MEDICAL DEVICE, AND METHOD FOR PRODUCING SAME | Toray Industries, Inc. (JP) | 2019-02-06 | — | — | EP | disclosed |
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090009852-A1 | ELECTROPHORETIC PARTICLES AND PROCESSES FOR THE PRODUCTION THEREOF | E INK CORPORATION (US) | 2009-01-08 | — | — | US | disclosed |
| US-7411720-B2 | Electrophoretic particles and processes for the production thereof | E INK CORPORATION (US) | 2008-08-12 | — | — | US | disclosed |
| US-20070128352-A1 | ELECTROPHORETIC PARTICLES AND PROCESSES FOR THE PRODUCTION THEREOF | E INK CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
| EP-0721454-A1 | NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST | J. URIACH & CIA. S.A. (ES) | 1996-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | ADSL, SLC19A1, SLC25A21 | MMP1 3530/4885MMP2 2658/4885MMP3 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.